Cargando…

Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19

Vaccinated, non-vaccinated, and immunosuppressed individuals will continue to be infected with SARS-CoV-2. Therefore, there is a priority to develop treatments that reduce the severity of COVID-19 in patients who require hospital admission. Interleukin-6 (IL-6) is a proinflammatory cytokine. In 2011...

Descripción completa

Detalles Bibliográficos
Autor principal:	Parums, Dinah V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299871/ https://www.ncbi.nlm.nih.gov/pubmed/34276042 http://dx.doi.org/10.12659/MSM.933973

Ejemplares similares

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023)

Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2021)

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
por: Araki, Manabu, et al.
Publicado: (2012)

Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis
por: Hashimoto, Motomu, et al.
Publicado: (2014)

Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα/gp130 hexameric signaling complex formation
por: Chou, Chun-Chi, et al.
Publicado: (2022)

Editorial: The First Monoclonal Antibody Vaccine to Prevent Malaria Heralds a New Era of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP)
por: Parums, Dinah V.
Publicado: (2021)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
por: Dufranc, Etienne, et al.
Publicado: (2020)

Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
por: Araki, Manabu, et al.
Publicado: (2014)

Dual STAT-3 and IL-6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL-6/IL-6R/STAT-3 axis
por: Méndez-Clemente, Anibal, et al.
Publicado: (2022)

Association of Polymorphisms of IL-6 Pathway Genes (IL6, IL6R and IL6ST) with COVID-19 Severity in an Amazonian Population
por: Rodrigues, Fabíola Brasil Barbosa, et al.
Publicado: (2023)

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
por: Shima, Yoshihito, et al.
Publicado: (2010)

Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells
por: Lokau, Juliane, et al.
Publicado: (2020)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
por: Garbers, Christoph, et al.
Publicado: (2021)

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
por: Saavedra, Danay, et al.
Publicado: (2020)

Tocilizumab, an IL6-receptor antibody, proved effective as adjuvant therapy for cytokine storm induced by severe infection in patients with hematologic malignancy
por: Wang, Bingjie, et al.
Publicado: (2023)

Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections
por: Parums, Dinah V.
Publicado: (2021)

Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis
por: Sainz, Luis, et al.
Publicado: (2022)

Editorial: The National COVID Cohort Collaborative Consortium Combines Population Data with Machine Learning to Evaluate and Predict Risk Factors for the Severity of COVID-19
por: Parums, Dinah V.
Publicado: (2021)

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
por: Galván-Román, José María, et al.
Publicado: (2021)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 – Authors' reply
por: Bovijn, Jonas, et al.
Publicado: (2021)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
por: Zhang, Yinqiang, et al.
Publicado: (2022)

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
por: Michot, J.-M., et al.
Publicado: (2020)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
por: Kaye, Avi Gurion, et al.
Publicado: (2020)

Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer
por: Heo, Tae-Hwe, et al.
Publicado: (2016)

The paradoxical effect of IL-6 and implications for the use of Tocilizumab in Covid-19 patients
por: Bruzzese, Vincenzo, et al.
Publicado: (2020)

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6
por: Li, Pan, et al.
Publicado: (2021)

Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19
por: Parums, Dinah V.
Publicado: (2021)

The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2014)

Clinical Value of IL6R Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis
por: Sainz, Luis, et al.
Publicado: (2022)

IL6/IL6R genetic diversity and plasma IL6 levels in bipolar disorder: An Indo-French study
por: Sundaresh, Aparna, et al.
Publicado: (2019)

Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R
por: Cupido, Arjen J., et al.
Publicado: (2022)

COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not
por: Silberstein, Morry
Publicado: (2021)

The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill
por: Knight, Jennifer M., et al.
Publicado: (2021)

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases
por: Nagao, Azusa, et al.
Publicado: (2014)

Tocilizumab (Anti-IL-6R) Suppressed TNFα Production by Human Monocytes in an In Vitro Model of Anti-HLA Antibody-Induced Antibody-Dependent Cellular Cytotoxicity
por: Shin, Bong-Ha, et al.
Publicado: (2017)

Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19
por: Parums, Dinah V.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uefk99ois5f8f25js9q19cvh7h